ReNeuron : Preliminary results presentation for the year ended 31 March 2022

2022 PRELIMINARY RESULTS

THE CUSTOMISABLE EXOSOMES DELIVERY PLATFORM OPTIMISED FOR SPECIFIC DRUG DELIVERY NEEDS

4 July 2022

Iain Ross - Interim Executive Chairman

Catherine Isted - Chief Financial Officer

Dr. Randolph Corteling - Head of Research

DISCLAIMER

This Presentation is being supplied to you solely for your information and may not be reproduced, further distributed to any other person or published, in wholeor inpart, foranypurpose. Subjectto certain exceptions, this Presentation is not for distribution in the United States, Australia, Canada or Japan or any other jurisdiction where its distribution may constitutea violationof thelaws of such jurisdiction.

The information contained in this document ("Presentation") has been prepared by ReNeuron Group plc (the "Company") and neither this Presentation, nor the information contained in itshould beconsidered a recommendation by the Company or any of its shareholders, directors, officers, agents, employees or advisers in relation to any purchase of the Company's securities, includingany purchase of or subscription for any shares (or securities convertible into shares) in the capital of the Company. This Presentation has not been fully verified and is subject to material updating, revisionand further amendment. Any person who receives this Presentation should not rely or act upon it. This Presentation should not be re-distributed,re-published, reproduced or disclosed by recipients, in whole or in part.

While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefor is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

This Presentation may contain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements and past performance is no guarantee of future performance. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, revenue generation, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Presentation and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation.

This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000.

In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent. This Presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. In particular, this Presentation is for information purposes and does not constitute an offer or invitation to subscribe for or purchase any securities in the United States. The securities of the Company have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold, pledged, delivered, distributed or transferred, directly or indirectly, into or in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in accordance with any applicable state securities laws. There will be no public offering of the securities of the Company in the United States.

By participating in and/or accepting delivery of this Presentation you agree to be bound by the foregoing restrictions and the other terms of this disclaimer.

ORGANISATIONAL HIGHLIGHTS

1. In July 2021, Iain Ross was appointed as Non-Executive Chairman and following Olav Hellebø's resignation as CEO in February 2022, Mr Ross became Interim Executive Chairman until the appointment of a new CEO

1. In October 2021, Catherine Isted, ACMA, joined the Board, replacing Michael Hunt as Chief Financial Officer

1. Additionally, during the period, the Board was reconfigured with former Chairman, Dr Tim Corn and Non-Executive directors Mark Evans and Sir Chris Evans OBE stepping down. Two new independent Non-Executive directors, Barbara Staehelin and Martin Walton, have joined the Board

1. Additionally, Dr Stefano Pluchino was appointed as Chief Scientific Officer and Dr Randolph Corteling as Head of Research, greatly increasing the
   Group's exosomes expertise

Operational

• financial highlights

5